Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 DLBCL 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1

Interventions

Dexamethasone 64 Cyclophosphamide 35 pomalidomide 34 Lenalidomide 34 Rituximab 31 Bortezomib 30 venetoclax 28 fludarabine 27 Gemcitabine 21 carfilzomib 20 Paclitaxel 19 pembrolizumab 17 daratumumab 17 Cisplatin 16 Carboplatin 15 Calcium Dobesilate 14 Azacitidine 14 ibrutinib 12 Docetaxel 12 Cytarabine 12 obinutuzumab 11 Nivolumab 11 durvalumab 10 Injections 10 Doxorubicin 10 Bevacizumab 10 selinexor 9 cemiplimab 9 blinatumomab 9 Cetuximab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × vistusertib × Clear all

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡